AtaiBeckley (ATAI) Receivables (2023 - 2026)

AtaiBeckley's (ATAI) quarterly Receivables came in at $1.5 million in Q1 2026, up 119.49% quarter-over-quarter from $667000.0 in Q4 2025.

AtaiBeckley (ATAI) Receivables (2023 - 2026) Analysis & Trends

AtaiBeckley's Receivables history runs 3 years deep, the most recent figure standing at $1.5 million for Q1 2026.

  • On a quarterly basis, Receivables changed N/A year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $1.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $667000.0, up 88.42% from the prior year.
  • Receivables improved to $1.5 million in Q1 2026 per ATAI's latest filing, from $667000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $313000.0 in Q3 2024 to a low of $46000.0 in Q3 2025.
  • A 3-year average of $176000.0 and a median of $172500.0 in 2023 frame the typical range for Receivables.
  • Biggest YoY gain for Receivables was 88.42% in 2025; the steepest drop was 88.42% in 2025.
  • Year by year, Receivables stood at $354000.0 in 2024, then soared by 88.42% to $667000.0 in 2025, then soared by 119.49% to $1.5 million in 2026.
  • Per Business Quant, the three latest ATAI Receivables figures stand at $1.5 million (Q1 2026), $667000.0 (Q4 2025), and $354000.0 (Q4 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 4.97 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 938.02 Mn
4 NuCana 279.75 Bn 279.75 Bn - 1.13 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 2.00 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 5.73 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 1.93 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 AtaiBeckley 2.56 Bn 2.56 Bn - 46,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 1.46 Mn
Dec 31, 2025 667,000.00
Sep 30, 2025 46,000.00
Dec 31, 2024 354,000.00
Dec 31, 2024 261,000.00
Sep 30, 2024 313,000.00
Dec 31, 2023 84,000.00